¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15
±³À°ÀÏÀÚ : 2023-04-15
±³À°Àå¼Ò : ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦

±³À°ÁÖÁ¦ : Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ

´ã´çÀÚ : ´ëÇѳú¿°³ú¿°ÁõÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-2072-0629

À̸ÞÀÏ : encephalitis.office@kens.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:00~09:30 ÇöÀåµî·Ï ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:30~09:45 A 31-year-old female with Refractory Primary CNS Vasculitis: What is the next possible alternative therapy? ÀåÀ±Çõ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:45~10:00 Neuronal Intranuclear Inclusion Disease in an Adult Patient: A Diagnostic Challenge ½Å¿ë¿ì(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:00~10:15 A 46-year old man with new-onset seizures È«»óºó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:15~10:30 25-year-old woman with drug resistant epilepsy : A case of autoimmune epilepsy ÀÌÀ±°æ(µ¿¾Æ´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:30~10:50 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:50~11:05 A case of LGI-1 antibody encephalitis with schizophrenia like symptom as an initial clinical manifestation ¼Û¿øºó(°¡Å縯°üµ¿´ë ±¹Á¦¼º¸ðº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:05~11:20 Scrub typhus ±è±ÙÅÂ(°è¸í´ëµ¿»êº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:20~11:35 A case of multiple cranial neuropathy after zoster ophthalmicus Ȳ¼ºÀº()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:35~11:50 An 18-year-old male with seizure and anti-N-methyl-D-aspartate receptor antibody ±èÅÂÁØ(¾ÆÁִ뺴¿ø)

½Ä»ç 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:50~13:00 LUNCH ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:00~13:25 VTE treatment and Prophylaxis for Neurologic patient ³ª»óÈÆ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:25~13:50 Immunotherapy and infection risk ÀÌÇÑ»ó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:50~14:15 Psychiatric symptom care in neurologic ward ±è¹Î¾Æ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:15~14:40 Breaking bad news and ethical decision À̼øÅÂ(¼­¿ï´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:40~15:00 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:00~15:25 Glymphatic evaluation using MRI ÃÖ½ÂÈ«(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:25~15:50 Macrophage activation syndrome ¹ÚÁø±Õ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:50~16:15 Seizure management in encephalitis patients ÁÖ°Ç(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 16:15~16:40 Recent Advances in Gene Therapy for Rare Diseases ¹®Àå¼·(¼­¿ï´ëº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦43ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2023-04-15
´ÙÀ½±Û ±¹¸³Áß¾ÓÀÇ·á¿ø Àü¹® ±âµµ°ü¸® ½Ã¹Ä·¹ÀÌ¼Ç : 2023-04-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21182 °æ±â Á¦6ȸ °¡Å縯´ëÇб³ ¼ººó¼¾Æ®º´¿ø ¾Ï ½ÉÆ÷Áö¾ö(¿ÀÇÁ¶óÀÎ/¿Â¶óÀÎ) : 2024-07-26 0 2 2024-07-02
21181 ´ë±¸ Çѱ¹¿©ÀÚÀÇ»çȸ ´ë±¸°æºÏÁöȸ 7¿ù Çмú½ÉÆ÷Áö¾ö(ºÒ¸éÁõ, ¼ö¸éÁ¦, Ȳ¹Ýº¯¼º ¹× ³ëÈ­ °ü·Ã ¾ÈÁúȯ) : 2024-07-23 0 7 2024-07-02
21180 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ) Á¦12ȸ ¼­¿ï ÀÓ»ó¾îÁö·³Áõ ¼¼¹Ì³ª : 2024-07-21 0 7 2024-07-02
21179 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ÇнÀÀå¾Ö ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-07-21 0 10 2024-07-02
21178 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú½ºÆ÷Ã÷ÀÇÇÐȸ - Á¦2Â÷ ½ºÆ÷Ã÷ ¼Õ»ó ½ÉÆ÷Áö¾ö : 2024-07-21 0 5 2024-07-02
21177 ¼­¿ï PH Korea 2024 with 4th EASOPH(Á¦9ȸ Æó°íÇ÷¾Ð Çмú´ëȸ) (2ÀÏÂ÷) : 2024-07-20 0 3 2024-07-02
21176 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦2ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-20 0 6 2024-07-02
21175 ¼­¿ï 21st Head and Neck Workshop (»ï¼º¼­¿ïº´¿ø & ´ëÇѵΰæºÎ¿Ü°úÇÐȸ) : 2024-07-20 0 1 2024-07-02
21174 ¼­¿ï 2024 ´ëÇÑÈ£Èí°ü¸®ÇÐȸ Á¦32Â÷ Çмú´ëȸ : 2024-07-20 0 5 2024-07-02
21173 ¼­¿ï 2024³â ´ëÇÑ°íÇ÷¾ÐÇÐȸ ´ë»çÁõÈıº¿¬±¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-07-20 0 4 2024-07-02
21172 ¼­¿ï Á¦4ȸ ´ëÇѼÒÈ­±âÇÐȸ °æ±âÀÎõÁöȸ ½ÉÆ÷Áö¾ö ¹× ¿¬±¸°úÁ¦ ¹ßǥȸ : 2024-07-20 0 4 2024-07-02
21171 ¼¼Á¾ 2024³â ´ëÇÑ°í°üÀýÇÐȸ °üÀýº¸Á¸ ½ÉÆ÷Áö¿ò : 2024-07-20 0 3 2024-07-02
21170 ¿ï»ê 2024³â Á¦7ȸ ´ëÇÑÇ׳ëÈ­ºñ´¢ÅëÇÕ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-20 0 3 2024-07-02
21169 ¼­¿ï PH Korea 2024 with 4th EASOPH(Á¦9ȸ Æó°íÇ÷¾Ð Çмú´ëȸ) (1ÀÏÂ÷) : 2024-07-19 0 2 2024-07-02
21168 ¼­¿ï ´ëÇÑ»çȸÁ¤½ÅÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-19 0 10 2024-07-01
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷